The Treatment Action Group (TAG) today expressed disappointment that SMART, a large, international study comparing CD4-guided, intermittent antiretroviral therapy to continuous treatment, has had to be stopped due to a significantly higher incidence of clinical events in the intermittent treatment arm.
What’s in the Pipeline: New HIV Drugs, Vaccines, Microbicides, HCV and TB Treatments in Clinical Trials By Rob Camp, Richard Jefferys, Tracy Swan & Javid Syed Edited by Mark Harrington & Bob Huff July 2005 From the Introduction: This overview…
TREATMENT ACTION GROUP SUPPORTS ACCELERATED F.D.A. APPROVAL FOR NOVEL PROTEASE INHIBITOR TIPRANAVIR NEW YORK, NY, 19 May 2005 Rob Camp, Antiretoviral Project Director for the Treatment Action Group (TAG), today testified in favor of Food and Drug Administration (FDA) accelerated…
2004 issues (December, October, September, August, July, June, May, April, March, February, January) of TAGline
By Bob Huff December 2004 Introduction The 3rd International Community TB/HIV Workshop was held in Paris from October 26-29, 2004. Participants were nominated by organizations and networks from all regions. From 229 applicants the Advisory Committee — Beverley Figaji (Namibia),…
The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is the annual meeting of the American Society for Microbiology. In 2004, it happened in Washington DC from 30 Oct to 2 Nov. Some new drugs were presented along with data…
September 2004 By Rob Camp In January 2003, W announced PEPFAR, The President's Emergency Plan For AIDS Relief, pledging 15 billion dollars of funding over 5 years, to provide testing and treatment in 15 countries affected by HIV/AIDS. Critique of…
Regarding the U.S. Military/NIAID-Sponsored RV144 ALVAC/AIDSVAX "Prime-Boost" Vaccine Trial in Thailand By Richard Jefferys September 28, 2004 On September 23, 2004, the US Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee held a hearing to discuss the…
The Difference Between Drugs and New Drugs By Rob Camp August 2004 FDA announced approvals in early August of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents for the treatment of HIV-1 infection. FDCs are…